Hormonal
GLP-1 receptor agonists significantly reduce the risk of major adverse cardiovascular events (MACE), cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure in both patients with type 2 diabetes and overweight/obese patients without diabetes.
If you have type 2 diabetes or are overweight/obese with cardiovascular risk factors, GLP-1 receptor agonists (like semaglutide or liraglutide) can significantly lower your risk of heart attacks, strokes, and heart failure hospitalizations, regardless of whether you have diabetes. These benefits are seen with both daily and weekly formulations, and oral options exist.
Patients on GLP-1 RAs had lower risk of major adverse cardiovascular events (MACE) (RR 0.87, 95% CI 0.82−0.93), cardiovascular death (RR 0.88, 95% CI 0.82−0.94), myocardial infarction (MI) (RR 0.87, 95% CI 0.77−0.97), stroke (RR 0.86, 95% CI 0.80−0.92), and hospitalization for heart failure (RR 0.90, 95% CI 0.83−0.98).
Why this rating
Meta-analysis of 24 randomized-controlled trials involving over 94,000 participants.
Source
Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials
Alireza Hosseinpour et al. · Clinical Cardiology · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →